Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | GPR6 | P46095 | 5/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937675 | 1.00 | ROCK2 (0.47) | ROCK2ROCK1GAANSD2PIK3CD | |
| SCHEMBL1936072 | 0.90 | ROCK2 (0.39) | ROCK2ROCK1PIK3CDGPR6IRAK4 | |
| SCHEMBL1937270 | 0.90 | LMNA (0.41) | ROCK2ROCK1GPR6IRAK4KCNH2 | |
| SCHEMBL1937269 | 0.90 | LMNA (0.41) | ROCK2ROCK1GPR6IRAK4KCNH2 | |
| SCHEMBL1936073 | 0.90 | ROCK2 (0.39) | ROCK2ROCK1PIK3CDGPR6IRAK4 | |
| SCHEMBL2176008 | 0.89 | ROCK2 (0.38) | ROCK2ROCK1GPR6IRAK4GPR119 | |
| SCHEMBL2176013 | 0.89 | ROCK2 (0.38) | ROCK2ROCK1GPR6IRAK4GPR119 | |
| SCHEMBL1937249 | 0.89 | GAA (0.39) | ROCK2ROCK1GAANSD2PIK3CD | |
| SCHEMBL1937247 | 0.89 | GAA (0.39) | ROCK2ROCK1GAANSD2PIK3CD | |
| SCHEMBL2180287 | 0.88 | ROCK2 (0.38) | ROCK2ROCK1GPR6IRAK4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885GAA 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.